Cost-effectiveness of TPMT Pharmacogenetics

"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~* Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~* Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~* Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"

"Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"